EW SEC Filings

Edwards Lifesciences Corporation (EW) has filed an 8-K report on February 10, 2026, to announce its financial results for the fourth quarter of 2025. While the 8-K itself is brief and primarily serves to incorporate the details from a furnished press release (Exhibit 99.1), the core information pertains to the company's performance in the latest reported quarter. Investors should review the accompanying press release for specific figures on revenue, profitability, and any forward-looking guidance provided by the company.

Edwards Lifesciences Corporation (EW) announced on January 11, 2026, that its proposed acquisition of JenaValve Technology, Inc. has been blocked by a preliminary injunction granted by the U.S. District Court for the District of Columbia at the request of the U.S. Federal Trade Commission (FTC). Consequently, the transaction will not proceed as planned. This development is a significant setback for Edwards Lifesciences' strategic growth initiatives and integration plans that hinged on the acquisition of JenaValve. Investors should focus on the implications of this failed acquisition, including potential impacts on future revenue streams, market positioning, and the company's capital allocation strategy. While the financial terms of the deal and any termination fees are not detailed in this 8-K, this event signifies a need for management to reassess its inorganic growth strategy and potentially seek alternative avenues for market expansion or product portfolio enhancement. The company's stock performance may be influenced by market reaction to this news and any subsequent management commentary.

Edwards Lifesciences Corporation reported a solid third quarter for 2025, with net sales reaching $1.55 billion, a 14.7% increase year-over-year. This growth was primarily driven by strong performance in their Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) product lines, demonstrating continued market leadership and product adoption. While overall sales showed robust growth, net income attributable to Edwards Lifesciences Corporation for the quarter was $291.1 million, a decrease compared to the same period last year. This was influenced by several factors including significant litigation expenses ($90.4 million), an intangible asset impairment charge of $40.0 million, and an unfavorable impact from foreign currency fluctuations. Despite these headwinds, the company's core operations in structural heart disease remain strong, with continued investment in research and development to fuel future innovation.

Edwards Lifesciences Corporation (EW) has filed an 8-K report on October 30, 2025, to disclose its financial results for the third quarter of 2025. The report primarily references a press release, dated October 30, 2025, which contains the detailed financial outcomes for the period. Investors should refer to this press release (Exhibit 99.1) for comprehensive information regarding the company's performance, including revenue, profitability, and any key operational metrics. This filing serves as notification of these results and does not represent new financial statements being filed directly within the 8-K. The furnished information under Item 2.02, including the press release, is not considered 'filed' for the purposes of the Securities Exchange Act of 1934, meaning the company retains protection against potential liabilities associated with such information until officially filed in subsequent reports. Investors are encouraged to review the press release for a full understanding of the company's third-quarter performance.

Edwards Lifesciences Corporation (EW) announced a significant leadership change via an 8-K filing on October 30, 2025. Chief Financial Officer (CFO) Scott Ullem has informed the company of his decision to transition out of his role by mid-2026. This development triggers an active search for a successor to lead the company's financial strategy. While the departure is planned for mid-2026, the immediate focus for investors is the initiation of the CFO selection process. This transition, though not immediate, is a key event that warrants attention as the company navigates its financial future. Investors will be keen to understand the timeline for appointing a new CFO and the potential impact on the company's financial management and strategic direction.

Edwards Lifesciences Corporation (EW) has announced its entry into an accelerated share repurchase (ASR) agreement, as detailed in an 8-K filing dated August 19, 2025. This strategic move indicates the company's commitment to returning capital to shareholders and reflects management's confidence in the company's financial health and future prospects. Investors should note that ASR agreements typically involve repurchasing a significant amount of stock in a short period, which can positively impact earnings per share and signal a belief by the company that its stock is undervalued. The press release filed as Exhibit 99.1 provides further details on the terms and expected impact of this repurchase program.

Edwards Lifesciences Corporation (EW) has announced a significant development regarding its proposed acquisition of JenaValve Technology, Inc. In a press release issued on August 6, 2025, the company disclosed that the U.S. Federal Trade Commission (FTC) has initiated action to block this acquisition. This news represents a key event for the company and its investors, potentially impacting strategic growth plans and financial outlook. While the specifics of the FTC's reasoning are not detailed in this 8-K filing, the blocking of the acquisition by a regulatory body signals potential challenges in executing strategic M&A activities. Investors should monitor future communications from Edwards Lifesciences for updates on the company's response to the FTC's decision and any potential alternative strategies for market expansion or technological integration.

Edwards Lifesciences Corporation (EW) reported strong top-line growth in its second quarter and first six months of 2025, with net sales increasing by 11.9% and 9.1% respectively compared to the prior year. This growth was primarily driven by robust performance in Transcatheter Aortic Valve Replacement (TAVR) and a significant surge in Transcatheter Mitral and Tricuspid Therapies (TMTT) sales, up 61.9% and 60.1% for the respective periods. The company also saw continued growth in its Surgical Structural Heart segment. While revenue growth was positive, gross profit margin experienced a slight decline due to higher manufacturing expenses for new therapies and foreign currency impacts. The company also recorded a notable loss on impairment of $47.1 million related to an unexercised acquisition option. The balance sheet shows an increase in cash and cash equivalents and a decrease in accounts payable. Investors should monitor the company's ongoing litigation and tax matters, particularly the significant IRS transfer pricing dispute, which continues to present a potential financial risk.

Edwards Lifesciences Corporation (EW) has filed an 8-K report detailing a significant executive departure. Larry L. Wood, Corporate Vice President and Group President for Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart, has resigned to pursue an opportunity outside the cardiovascular industry. Mr. Wood's resignation is effective September 1, 2025. This change in leadership, particularly within the TAVR segment, is a key development for investors to monitor. While the departure is for a non-competitive reason, the transition of responsibilities will be crucial. Daniel J. Lippis, currently overseeing key Asian markets, will assume leadership for the TAVR business unit. Investors should assess the company's communication regarding the strategic implications of this transition and Mr. Lippis's ability to drive the TAVR segment forward.

Edwards Lifesciences Corp (EW) has filed a Form 8-K reporting its financial results for the second quarter of 2025, as of July 23, 2025. The primary focus of this filing is the issuance of a press release detailing the company's performance during the quarter. Investors should refer to the furnished press release (Exhibit 99.1) for specific financial figures, including revenue, earnings per share, and any commentary on operational performance and outlook. While the 8-K itself does not contain the detailed financial data, it serves as the official notification of the release of this information. The press release is expected to provide insights into key growth drivers, segment performance (such as transcatheter aortic valve replacement - TAVR, and critical care), and any forward-looking guidance provided by the company. Investors should carefully review Exhibit 99.1 for a comprehensive understanding of Edwards Lifesciences' recent financial health and future expectations.

Edwards Lifesciences Corporation (EW) has filed an 8-K report detailing the outcomes of its 2025 Annual Meeting of Stockholders. The primary financial information relevant to investors concerns the approval of amendments to the company's Employee Stock Purchase Plans (ESPPs). Stockholders overwhelmingly approved the amendment and restatement of both the U.S. ESPP and the International ESPP, significantly increasing the number of shares available for issuance under these plans. This move indicates a continued commitment to employee stock ownership and may signal management's anticipation of future stock price appreciation, as more shares will be available for purchase by employees at potentially favorable prices.

Edwards Lifesciences Corporation reported solid financial results for the first quarter of 2025, with net sales increasing by 6.2% to $1.41 billion, primarily driven by growth in their Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) product lines. Diluted earnings per share also saw an increase, reflecting improved operational performance. The company continued its strategic focus on structural heart disease innovations, with recent FDA approval for the SAPIEN 3 platform for asymptomatic severe aortic stenosis patients and CE Mark for the SAPIEN M3 mitral valve replacement system. Financially, the company maintained a strong balance sheet with a significant cash position. While operating activities provided substantial cash flow, driven partly by a tax payment normalization from the prior year, investing activities also saw significant deployment into available-for-sale investments. The company also returned capital to shareholders through share repurchases, including a notable accelerated share repurchase program. However, investors should note ongoing litigation and tax disputes, particularly an IRS examination regarding transfer pricing, which represent potential future financial impacts, although management does not currently believe they will be material adverse events.

Edwards Lifesciences Corporation (EW) has filed an 8-K report on April 23, 2025, announcing its financial results for the first quarter of 2025. The primary driver of this filing is the press release furnished as Exhibit 99.1, which details the company's performance during the period ending April 22, 2025. Investors should refer to this press release for specific financial metrics, including revenue, profitability, and any forward-looking guidance provided by the company.

Edwards Lifesciences Corporation reported strong performance in its 2024 fiscal year, with net sales reaching $5.4 billion, an increase of 8.6% year-over-year. This growth was primarily driven by robust sales in its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments. The company also made significant strategic moves, including the sale of its Critical Care product group for $4.2 billion and several key acquisitions aimed at strengthening its position in structural heart disease and expanding into heart failure management. Key financial highlights include a notable increase in net income and diluted earnings per share, supported by top-line growth and the positive impact of the Critical Care divestiture. The company's commitment to innovation is evident in its continued investment in research and development, representing 19% of net sales in 2024, with advancements in its TAVR and TMTT platforms. Edwards Lifesciences remains focused on its patient-centric strategy, aiming to transform care for those with structural heart disease and expanding its reach in interventional heart failure technologies.

Edwards Lifesciences Corporation (EW) has filed an 8-K report on February 11, 2025, to announce its fourth quarter 2024 financial results. The primary purpose of this filing is to provide investors with the official release of the company's performance metrics for the period ending December 31, 2024. This report serves as the primary source for detailed financial outcomes, including revenue, profitability, and other key operational indicators that shape the company's current financial standing. Investors should pay close attention to the press release, furnished as Exhibit 99.1, which contains the comprehensive financial details for the fourth quarter of 2024. While this 8-K filing itself does not contain the detailed financial statements, it directs stakeholders to the official press release for these critical figures. The information provided in this release will be instrumental in assessing the company's recent performance and its implications for future financial health and strategic direction.

Edwards Lifesciences Corporation (EW) reported a strong third quarter and nine-month period ending September 29, 2024, characterized by significant revenue growth and strategic divestitures. The company's core structural heart business demonstrated robust performance, with net sales increasing by 8.9% for the quarter and 8.3% for the nine months, driven by strong demand for its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) products. A major highlight was the completion of the sale of its Critical Care product group for $4.2 billion, which contributed a substantial gain to net income and allows the company to sharpen its focus on implantable medical innovations. Financially, the company reported a significant increase in net income, largely influenced by the gain from the Critical Care divestiture. Operating income also showed positive trends, reflecting disciplined expense management and strong sales. The company also made strategic acquisitions, including Endotronix, Inc. and JC Medical, Inc., to further strengthen its heart failure and structural heart portfolios, respectively. Despite these strategic moves and operational successes, investors should remain aware of ongoing litigation and tax matters that could present future uncertainties.

Edwards Lifesciences Corporation (EW) has filed a Form 8-K to report its financial results for the third quarter of 2024, as detailed in a press release dated October 24, 2024. While the filing itself is brief and primarily serves to incorporate the press release, the information contained within that release is crucial for investors to understand the company's recent performance and financial condition. Investors should focus on the details within the furnished press release (Exhibit 99.1) for specific figures regarding revenue, profitability, and any forward-looking guidance. This 8-K signals the official release of Q3 2024 earnings and provides the foundational data upon which further analysis of the company's operational success and strategic direction can be built. The filing itself does not contain new financial statements or operational commentary beyond referencing the press release.

Edwards Lifesciences Corporation (EW) announced the completion of the sale of its Critical Care product group to Becton, Dickinson and Company on September 3, 2024. This divestiture marks a significant strategic shift for Edwards, allowing it to focus more intently on its core cardiovascular businesses. Investors should note that this transaction is expected to reshape the company's operational and financial profile moving forward. Concurrently, the company's Board of Directors approved a substantial $1.5 billion increase in its share repurchase authorization, alongside entering into a $500 million accelerated share repurchase agreement. These capital allocation decisions signal a strong commitment to returning value to shareholders and reflect management's confidence in the company's future prospects and financial flexibility post-divestiture. Investors will want to monitor how these buyback programs are executed and their impact on EPS.

Edwards Lifesciences Corporation (EW) reported solid financial results for the second quarter and the first six months of 2024, demonstrating continued growth in its core structural heart disease business. Net sales increased by 7.0% year-over-year for the quarter and 7.9% for the first six months, primarily driven by strong performance in Transcatheter Aortic Valve Replacement (TAVR) and significant growth in Transcatheter Mitral and Tricuspid Therapies (TMTT). The company is strategically divesting its Critical Care product group, having entered into a definitive agreement for its sale in June 2024. This move is expected to sharpen focus on core growth areas and allow for reinvestment in interventional heart failure technologies. While the sale is pending regulatory approval, the financial results reflect Critical Care as discontinued operations. Despite some headwinds, including lower-than-expected TAVR growth in the US and currency fluctuations impacting gross margins, the company maintains a positive outlook, supported by ongoing investments in R&D and strategic acquisitions. Key financial highlights include continued revenue growth, robust operating income, and effective management of operating expenses. The company also provided updates on its ongoing tax litigations, which remain a significant contingency but are being actively managed. Overall, the report indicates a company strategically positioning itself for future growth while navigating competitive and regulatory landscapes.

Edwards Lifesciences (EW) has filed an 8-K report detailing significant corporate developments beyond its second-quarter 2024 financial results. The company announced two strategic acquisitions: JenaValve Technology, Inc., a company focused on transcatheter treatment of aortic regurgitation, and Endotronix, Inc., known for its FDA-approved Cordella Sensor for pulmonary artery pressure monitoring. These acquisitions represent a substantial investment, with an upfront cash payment of approximately $1.2 billion and potential additional milestone payments of up to $445 million. The strategic rationale appears to be strengthening Edwards' position in the structural heart disease market and expanding its portfolio of innovative medical devices. While the 8-K incorporates the press release detailing Q2 2024 financial results (Exhibit 99.1), the primary focus of the filing for investors is the news of these two significant acquisitions. The acquisitions are subject to customary closing conditions, and the company has provided forward-looking statements outlining potential risks and uncertainties associated with their completion and integration. Investors should pay close attention to the closing status and future performance contributions of these newly acquired entities.

Edwards Lifesciences Corporation (EW) announced on July 15, 2024, that it has exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage company focused on transcatheter mitral valve replacement (TMVR) technology. This strategic move signals EW's intent to bolster its position in the rapidly growing structural heart market, particularly in the complex mitral valve space. The acquisition is expected to close by the end of 2024, with an approximate cash consideration of $300 million. While the financial terms are substantial, the potential to integrate Innovalve's early-stage TMVR technology could represent a significant long-term growth opportunity for Edwards Lifesciences, aligning with its existing portfolio and expertise in minimally invasive cardiac procedures.

Edwards Lifesciences Corporation (EW) has announced a significant addition to its Board of Directors with the appointment of David T. Feinberg, M.D., effective immediately. Dr. Feinberg brings a wealth of experience spanning nearly three decades in health system management and health information technology services. His extensive background includes leadership roles at prominent organizations such as Oracle Health (Chairman), Cerner Corporation (CEO), Google Health (Vice President), and Geisinger Health (President and CEO), as well as significant experience within UCLA Health. This appointment is particularly noteworthy given Dr. Feinberg's deep expertise in healthcare operations, technology, and quality improvement, which are highly relevant to Edwards Lifesciences' mission in advanced medical technologies. His role as a member of the Board's Audit Committee will further enhance the board's oversight capabilities. Investors may view this as a positive development, signaling a continued focus on strategic growth and operational excellence within the company.

Edwards Lifesciences Corp (EW) announced a key leadership change within its finance department. Robert W.A. Sellers, the current Senior Vice President and Principal Accounting Officer, will retire effective July 1, 2024. This retirement marks the end of Mr. Sellers' tenure, and the company has promptly named his successor. Andrew M. Dahl, who joined Edwards in February 2024 as Senior Vice President and Corporate Controller, will step into the role of Principal Accounting Officer upon Mr. Sellers' retirement. Mr. Dahl brings a wealth of experience from his previous roles at Medtronic PLC, Polaris Industries, and Deloitte & Touche LLP, including extensive background in financial reporting and controls. The company has confirmed that Mr. Dahl's appointment is standard and he has no material business relationships or family ties that would require disclosure under SEC regulations.

Edwards Lifesciences Corporation (EW) has announced a significant strategic shift via an 8-K filing on June 3, 2024. The company has entered into a Stock and Asset Purchase Agreement to sell its Critical Care product group to Becton, Dickinson and Company for $4.2 billion in cash. This divestiture represents a major change in the company's portfolio and is a substantial cash inflow. In conjunction with this sale, Edwards Lifesciences has also announced it is abandoning its previously planned spin-off of the Critical Care business. Investors should focus on the strategic implications of this sale, the use of proceeds from the $4.2 billion transaction, and how this will shape the future direction of Edwards Lifesciences, particularly its core structural heart and critical care businesses. The filing also includes forward-looking statements detailing potential risks and uncertainties related to the closing of the transaction.

Edwards Lifesciences Corporation (EW) has filed an 8-K report detailing the results of its Annual Meeting of Stockholders held on May 7, 2024. The filing confirms the election of all director nominees, with substantial support from shareholders. Additionally, shareholders provided advisory approval for the company's executive compensation, ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and approved the Amended and Restated Long-Term Stock Incentive Compensation Program. These outcomes indicate strong shareholder confidence in the company's leadership, financial oversight, and long-term incentive structures. For investors, the overwhelming support for director nominees and the approval of key proposals signal stability and alignment between management and the shareholder base. The ratification of the auditor and the incentive program are routine but important votes that maintain operational continuity and provide a framework for future executive performance and retention. The minimal 'against' votes on these matters, particularly executive compensation and the incentive program, suggest that current shareholder concerns, if any, are not widespread or are being addressed through other company communications.

Edwards Lifesciences Corporation reported solid revenue growth in the first quarter of 2024, with net sales increasing by 9.5% to $1.6 billion compared to the prior year. This growth was primarily driven by strong performance in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) product lines. The company also incurred significant separation costs related to the planned spin-off of its Critical Care product group, impacting net income. Operationally, the company continues to invest in research and development, essential for its long-term growth strategy in structural heart disease and related therapies. While the company generated positive operating income, the reported net cash used in operating activities was negative, largely due to a substantial tax deposit made related to a contested tax matter. Investors should monitor the progress of the Critical Care spin-off and the resolution of ongoing tax disputes, which could have future financial implications.

Edwards Lifesciences Corporation (EW) filed an 8-K on April 24, 2024, to report its financial results for the first quarter of 2024. The press release, furnished as an exhibit, details the company's performance during the period. Investors should note that this filing primarily serves to disseminate the Q1 2024 earnings information and does not contain new operational or strategic developments beyond what is presented in the earnings release. The core of this report is the Q1 2024 financial performance. While the filing itself does not provide the detailed numbers, it directs investors to the press release (Exhibit 99.1) for specific revenue, profitability, and other key financial metrics. Investors are encouraged to review the furnished press release for a comprehensive understanding of Edwards Lifesciences' recent financial standing and operational results.

Edwards Lifesciences Corporation (EW) announced significant changes to its Board of Directors, effective in conjunction with the upcoming 2024 Annual Meeting of Stockholders on May 7, 2024. Most notably, Michael A. Mussallem, the current Non-Executive Chairman, has decided to retire from his position and will not seek re-election to the Board. This marks the end of a long tenure for Mr. Mussallem, who has been instrumental in the company's leadership.

Edwards Lifesciences Corporation (EW) demonstrated solid performance in its 2023 fiscal year, with net sales reaching $6.0 billion, an increase of 11.6% year-over-year. This growth was primarily driven by its Transcatheter Aortic Valve Replacement (TAVR) segment, which accounted for 65% of total net sales, and a significant 70.1% increase in its Transcatheter Mitral and Tricuspid Therapies (TMTT) segment. The company continues to invest heavily in research and development, with 17.8% of net sales dedicated to innovation, particularly in advancing its TAVR and TMTT platforms, including recent FDA approval for its EVOQUE tricuspid valve replacement system. While the company navigated challenges such as COVID-19 impacts and macroeconomic headwinds, its strategic focus on structural heart disease and critical care monitoring remains robust. A significant event announced in late 2023 was the planned tax-free spin-off of its Critical Care product group, expected by the end of 2024. This strategic move aims to sharpen focus and allow for expanded opportunities within its core structural heart business and interventional heart failure technologies. Investors should note the ongoing significant tax matter with the IRS concerning transfer pricing, which could have future financial implications, though the company is contesting the assessment.

Edwards Lifesciences Corporation (EW) filed an 8-K on February 6, 2024, to announce its fourth-quarter 2023 financial results. While the filing itself is brief and primarily references an attached press release (Exhibit 99.1), the core information relates to the company's performance during the last quarter of 2023. Investors should review the furnished press release for detailed financial figures, including revenue, earnings per share, and any forward-looking guidance provided by management. This report serves as the official channel for disclosing these key financial metrics, which are crucial for assessing the company's operational success, profitability, and overall financial health. The filing indicates that the detailed results and commentary are available in the press release, making it the primary source for understanding EW's recent financial standing and future outlook.

Edwards Lifesciences Corporation (EW) announced a significant strategic shift at its 2023 Investor Conference, detailing plans to spin off its Critical Care product group by the end of 2024. This move is intended to be a tax-free transaction, allowing the company to focus on its core transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapies (TMTT) businesses, while the Critical Care segment will operate as an independent entity. Investors should note that further details regarding the spin-off, including a Form 10 filing with the SEC, are anticipated in mid-2024. In addition to the strategic spin-off, the company's Board of Directors has approved an additional $1 billion in share repurchase authorization. This signals continued confidence in the company's financial health and commitment to returning capital to shareholders. The spin-off is expected to unlock value and allow for more focused capital allocation and strategic growth opportunities for both the remaining Edwards Lifesciences and the new independent Critical Care company.

Edwards Lifesciences Corporation reported solid revenue growth in the third quarter and first nine months of 2023, driven primarily by its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments. Net sales increased by 12.3% and 10.8% respectively for the three and nine-month periods, indicating strong market demand for their innovative cardiac solutions. Despite global economic uncertainties and prior-year charges, the company demonstrated improved profitability. The company's financial health remains robust, supported by healthy cash flows from operations and a strong liquidity position.

Edwards Lifesciences Corporation (EW) filed an 8-K on October 25, 2023, primarily to report its financial results for the third quarter of 2023. While the 8-K itself is brief and refers to an attached press release (Exhibit 99.1) for the detailed financial information, investors should focus on the content of that press release for performance insights. This filing signals the release of Q3 2023 earnings, which is a critical update on the company's operational and financial health.

Edwards Lifesciences Corporation's (EW) Q2 2023 10-Q filing shows a solid performance with a notable increase in net sales, driven primarily by its TAVR products, which saw a 9.3% rise year-over-year for the quarter. Total net sales grew 11.4% to $1.53 billion for the quarter, and 10.1% to $2.99 billion for the first six months. Despite revenue growth, diluted earnings per share decreased for the first six months of the year, largely impacted by a significant after-tax charge of $142.2 million related to an intellectual property agreement with Medtronic. The company also saw an increase in R&D expenses, reflecting continued investment in innovation, particularly in TAVR technologies. Key balance sheet changes include a substantial increase in cash and cash equivalents, up from $769.0 million at year-end 2022 to $1.04 billion at the end of Q2 2023. Goodwill also increased significantly due to a business combination. While the company operates in a challenging macroeconomic environment with lingering COVID-19 impacts and global economic uncertainties, its liquidity remains strong, with no amounts outstanding under its credit facility. Investors should monitor the ongoing tax litigation with the IRS, which could materially impact future financial statements.

Edwards Lifesciences Corporation (EW) filed an 8-K on July 26, 2023, announcing its financial results for the second quarter of 2023. The primary purpose of this filing is to provide investors with the company's performance metrics for the period. While the 8-K itself is brief, it references an attached press release (Exhibit 99.1) which contains the detailed financial results, including key performance indicators and operational updates. Investors should refer to the furnished press release for comprehensive details on revenue, earnings, and any forward-looking statements or business segment performance. This filing serves as official notification and dissemination of this important quarterly information, ensuring transparency for shareholders and the market. The information provided is crucial for assessing the company's current financial health and future prospects.

This 8-K filing from Edwards Lifesciences (EW) details several key events that occurred around their 2023 Annual Meeting of Stockholders on May 10th, 2023. Most notably, the company announced an increase in CEO Bernard J. Zovighian's annual base salary to $1,050,000 and an incentive pay target of $1,470,000. This compensation adjustment reflects his prior appointment as Chief Executive Officer. Furthermore, the filing reports on the outcomes of various shareholder proposals. All director nominees were elected, and shareholders approved the company's executive compensation on an advisory basis, favoring annual "say-on-pay" votes. A significant amendment to the company's Certificate of Incorporation to provide exculpation for officers, as permitted by Delaware law, was also approved by stockholders. However, a shareholder proposal requesting an independent board chairman policy was not approved. The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2023 was also ratified.

Edwards Lifesciences reported strong top-line growth for the first quarter of 2023, with net sales increasing by 8.8% to $1.46 billion, primarily driven by its Transcatheter Aortic Valve Replacement (TAVR) segment. The company also saw significant growth in its Transcatheter Mitral and Tricuspid Therapies (TMTT) segment, reflecting increasing adoption of its PASCAL system. While revenue growth was robust, net income saw a decline compared to the prior year, largely due to a significant after-tax charge of $30.5 million related to an intellectual property agreement with Medtronic. The company's balance sheet shows a healthy increase in cash and cash equivalents and a growth in goodwill, likely related to a recent business combination. Despite increased R&D and SG&A expenses, the company remains focused on innovation and expanding its product offerings, evidenced by ongoing clinical trials and new product launches. Investors should monitor the impact of the Medtronic intellectual property agreement and ongoing tax examinations, which present potential future financial uncertainties.

Edwards Lifesciences Corporation (EW) filed an 8-K on April 25, 2023, to report its financial results for the first quarter of 2023. The key information is contained within the press release (Exhibit 99.1) attached to this filing, which details the company's performance and financial condition as of and for the period ending in Q1 2023. Investors should review this press release for specific revenue, earnings, and any forward-looking guidance provided. While the 8-K itself is brief, it signifies the official release of quarterly financial data. The attached press release will offer a comprehensive overview of how Edwards Lifesciences performed against expectations, any significant operational updates, and management's outlook for the remainder of the fiscal year. This is a crucial report for understanding the company's current trajectory and making informed investment decisions.

Edwards Lifesciences Corporation (EW) has filed an 8-K report detailing amendments to its Bylaws, primarily related to director nominations and corporate governance. These changes, effective February 16, 2023, aim to align the company's procedures with new universal proxy rules (Rule 14a-19) and enhance the disclosure requirements for shareholder nominations. The amendments seek to provide greater clarity and robustness to the director nomination process, ensuring compliance and facilitating shareholder engagement within a structured framework. For investors, these updates signify a proactive approach by Edwards Lifesciences to modernize its governance practices. The incorporation of universal proxy rules and enhanced informational requirements for director nominees are designed to ensure a more efficient and transparent shareholder meeting process. While these changes do not directly impact the company's financial performance or strategic operations, they are crucial for maintaining good corporate governance, which can indirectly influence investor confidence and long-term shareholder value.

Edwards Lifesciences Corporation (EW) reported its 2022 full-year results, demonstrating resilience despite prevailing macroeconomic challenges and the lingering effects of the COVID-19 pandemic. The company achieved net sales of $5.4 billion, a 2.9% increase year-over-year, driven primarily by strong performance in its Transcatheter Aortic Valve Replacement (TAVR) segment, which represented 65% of total net sales. The company continues to invest heavily in research and development, with R&D expenses increasing by 5% year-over-year, representing 18% of sales, focusing on next-generation TAVR technologies and expanding its Transcatheter Mitral and Tricuspid Therapies (TMTT) offerings. Despite foreign currency headwinds that impacted international sales by $140.2 million, Edwards Lifesciences maintained effective foreign currency hedging programs, contributing to a gross profit increase. The company also saw growth in its Surgical Structural Heart and Critical Care segments. Management highlighted key regulatory approvals and product launches in 2022, including FDA approval for the MITRIS RESILIA valve and PASCAL Precision system, and the launch of the SAPIEN 3 Ultra RESILIA valve in the U.S. While the company is navigating various risks, including regulatory compliance, competition, and supply chain considerations, its strategic focus on innovation and patient-centric solutions positions it for continued leadership in the structural heart disease and critical care monitoring markets.

Edwards Lifesciences Corporation (EW) filed an 8-K on January 31, 2023, to announce its fourth-quarter 2022 financial results. This report primarily serves to furnish a press release containing the company's performance for the period ending December 31, 2022. Investors should refer to the furnished press release (Exhibit 99.1) for detailed financial figures and operational updates. The 8-K itself does not provide new quantitative financial data but directs stakeholders to the press release for the specifics of the Q4 2022 performance. Therefore, an analysis of the actual financial results and their implications requires a review of the accompanying press release, which covers topics such as sales, earnings, and any forward-looking guidance the company may have provided.

Edwards Lifesciences Corporation (EW) announced a significant leadership transition, with current CEO Michael A. Mussallem planning to retire from his CEO role at the company's Annual Meeting of Stockholders on May 11, 2023. Mr. Mussallem will transition to a non-executive Chairman of the Board position, ensuring continued strategic guidance. Bernard J. Zovighian, currently corporate vice president and general manager for the Transcatheter Mitral and Tricuspid Therapies (TMTT) business, has been appointed President effective January 1, 2023, and will succeed Mr. Mussallem as CEO on May 11, 2023. This planned succession aims to provide continuity and leverage Mr. Zovighian's extensive experience, particularly in the TMTT segment, which is a key growth area for Edwards. The company also announced compensation adjustments for Mr. Zovighian and Larry Wood, who is taking on an expanded role. These changes are part of a strategic move to position the company for future growth and innovation under new leadership, while retaining valuable experience at the board level.

Edwards Lifesciences Corporation (EW) announced on November 1, 2022, its entry into an Accelerated Share Repurchase Agreement (ASR). This move signifies management's confidence in the company's stock and its commitment to returning capital to shareholders. While the specific details of the ASR agreement, such as the total dollar amount or the number of shares to be repurchased, are not fully detailed in this 8-K filing itself, the press release incorporated by reference likely provides these crucial figures. Investors should review the associated press release for a comprehensive understanding of the share repurchase program's scope and potential impact on the company's financials and stock valuation.

Edwards Lifesciences Corporation (EW) reported its third-quarter 2022 financial results, showcasing modest top-line growth amidst a challenging macroeconomic environment. Net sales increased slightly year-over-year, primarily driven by the performance of Transcatheter Aortic Valve Replacement (TAVR) products, especially the Edwards SAPIEN platform. The company experienced some headwinds from foreign currency fluctuations, particularly impacting sales outside the United States. Operationally, the company recorded a significant special charge related to the exit of its HARPOON surgical mitral repair system program. Despite this, profitability remained robust, though diluted earnings per share saw a slight decrease compared to the prior year, influenced by factors like changes in contingent consideration liabilities and increased R&D and SG&A expenses. The company maintained a strong liquidity position and continued its share repurchase program, demonstrating confidence in its financial health and future prospects.

Edwards Lifesciences (EW) filed an 8-K on October 27, 2022, to announce its financial results for the third quarter of 2022. The filing primarily consists of a press release that details the company's performance during the period. Investors should pay close attention to the revenue, earnings per share, and any forward-looking guidance provided in the press release for a comprehensive understanding of the company's current financial health and future outlook.

Edwards Lifesciences Corporation (EW) reported its second quarter and year-to-date results for the period ending June 30, 2022. While overall net sales saw a slight increase of 4.7% to $2.7 billion for the first six months of the year, driven by Transcatheter Aortic Valve Replacement (TAVR) products, the company faced headwinds in the second quarter. Net sales for the three months ended June 30, 2022, were essentially flat year-over-year at $1.37 billion, impacted by slower-than-expected improvement in US hospital staffing and unfavorable foreign currency exchange rates. Despite these challenges, the company demonstrated strong operational execution, with gross profit increasing due to sales growth and a positive impact from its foreign currency hedging program. However, diluted earnings per share saw a decline for the six-month period, largely attributed to changes in the fair value of contingent consideration liabilities and increased operating expenses related to sales, marketing, and R&D investments. The company continues to invest heavily in innovation, particularly in its TAVR and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments, with significant clinical trial activity underway. Management remains confident in its liquidity and ability to fund its operations and strategic initiatives, including a substantial ongoing share repurchase program.

Edwards Lifesciences Corporation (EW) filed an 8-K on July 27, 2022, to announce its financial results for the second quarter of 2022. The report primarily references a press release issued on July 28, 2022, which contains the detailed financial outcomes for the quarter. Investors should refer to this press release for specifics on revenue, earnings, and any forward-looking guidance provided by the company.

Edwards Lifesciences Corporation (EW) announced on July 20, 2022, its entry into a new five-year credit agreement, effective July 15, 2022. This agreement establishes a $750 million multi-currency unsecured revolving credit facility, replacing the company's previous 2018 credit agreement. The new facility offers improved pricing and terms compared to its predecessor. The company has the option to increase the facility size by an additional $250 million, subject to lender approval. Borrowings under the new revolving facility will be subject to variable interest rates tied to the Secured Overnight Financing Rate (SOFR) or a base rate, plus an applicable margin based on leverage or debt ratings. The facility matures on July 15, 2027, and is intended for general corporate purposes, with no amounts borrowed as of the filing date. The agreement includes customary covenants and financial restrictions, such as a maximum leverage ratio.

Edwards Lifesciences Corporation (EW) filed an 8-K on May 4, 2022, detailing the results of its 2022 Annual Meeting of Stockholders held on May 3, 2022. The meeting's primary focus was on shareholder votes regarding director elections, executive compensation, auditor ratification, and a shareholder proposal. All incumbent directors were overwhelmingly re-elected, indicating strong shareholder confidence in the current board's leadership and strategy. Similarly, the advisory vote on executive compensation received majority approval, suggesting alignment between shareholder and management views on compensation practices. The ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, also passed with substantial support. This signifies continued trust in the company's financial reporting and audit processes. However, a shareholder proposal to lower the ownership threshold required to call a special meeting was notably not approved, highlighting a divergence in opinion on corporate governance mechanisms related to shareholder activism.

Edwards Lifesciences Corporation (EW) reported solid financial results for the first quarter of 2022, demonstrating resilience and growth in a challenging macroeconomic environment. Net sales increased by 10.2% to $1.34 billion compared to the prior year's first quarter, driven primarily by strong performance in Transcatheter Aortic Valve Replacement (TAVR) products, which saw an 11.3% increase in sales. This growth was supported by higher sales of the Edwards SAPIEN platform, particularly in the United States and Europe. The company also reported an increase in net income to $373.6 million, up from $338.2 million in the same period last year, translating to diluted earnings per share (EPS) of $0.59, up from $0.54. Despite the impact of the Omicron variant on hospital capacity in early 2022, Edwards Lifesciences successfully navigated these challenges, with operations outside the United States experiencing a less pronounced year-over-year impact from the pandemic. The company's strategic investments in R&D and new product development, including advancements in TMTT and Surgical Structural Heart portfolios, position it for continued future growth.